Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 42.61 1.49 (3.62%) Market Cap: 3.54 Bil Enterprise Value: 3.05 Bil PE Ratio: 0 PB Ratio: 24.36 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Cowen and Company Health Care Conference Transcript

Mar 12, 2019 / 02:00PM GMT
Release Date Price: $66.35 (+2.11%)
Yaron Werber
Cowen and Company - Analyst

Hey, good morning, everybody. And thanks for joining us on this second day here at the Cowen -- the 39th Annual Cowen Healthcare Conference in Boston. It's a great pleasure to introduce Emil Kakkis, CEO and President of Ultragenyx. Emil has founded the Company after founding originally BioMarin. And Ultragenyx is one of our topics for this year. So I think there is going to be a presentation here, and there's going to be a breakout session at the Exeter Room across the hall.

So, Emil, thank you for joining us. We appreciate it.

Emil Kakkis
Ultragenyx Pharmaceutical Inc. - President and CEO

Thanks, Yaron. It's been a long time. And good to see you back, back in the fold. So good morning, everyone. And we will give you an update on Ultragenyx in the last while.

Ultragenyx, a rare disease company, by design, from the beginning. How do you build the best rare disease company? You can. And we have been doing that with a number of new approaches which I'll touch on. We've also been building a gene therapy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot